Higashiyama M, Doi O, Kodama K, Yokuchi H, Inaji H, Tateishi R
Department of Thoracic Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases (formerly, The Center for Adult Diseases), Japan.
Anticancer Res. 1996 Jul-Aug;16(4B):2351-5.
We measured pS2 protein in the serum of patients with adenocarcinoma and non-adenocarcinoma types of lung cancer, non-cancerous lung lesions, and the control sera. Although the serum pS2 protein level in patients with lung adenocarcinoma was significantly higher than that in patients with other diseases, as well in control samples, it had little clinical value as a screening tumor marker because the levels in control samples showed a wide range of variation. However, analysis according to the histological subtype of lung adenocarcinoma, ordinary and bronchioloalveolar, revealed a high serum level of pS2 protein in several patients with advanced stage disease in the former, and mucus-producing goblet cell subtypes in the latter, which showed strong pS2 protein expression in tissues, whose serum levels diminished to the control level after resection. Thus, the serum levels of pS2 protein may be a useful marker of tumor burden in selected patients with lung adenocarcinoma.
我们检测了腺癌和非腺癌类型肺癌患者、非癌性肺病变患者以及对照血清中的pS2蛋白。虽然肺腺癌患者血清中的pS2蛋白水平显著高于其他疾病患者以及对照样本中的水平，但由于对照样本中的水平存在广泛差异，它作为筛查肿瘤标志物的临床价值不大。然而，根据肺腺癌的组织学亚型（普通型和细支气管肺泡型）进行分析发现，前一亚型中部分晚期疾病患者血清pS2蛋白水平较高，后一亚型中产生黏液的杯状细胞亚型组织中pS2蛋白表达强烈，其血清水平在切除术后降至对照水平。因此，pS2蛋白的血清水平可能是部分肺腺癌患者肿瘤负荷的有用标志物。
